Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hochhaus

Showing results (11-20 of 216) with videos related to

Pageof 22
Sort By:
Leukemia|June 25, 2004
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceA Hochhaus, P La Rosée
Leukemia|December 10, 2025
Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few moreR P Gale, A Hochhaus
Leukemia|December 13, 2024
Mpox in people with haematological cancersR P Gale, A Hochhaus
Der Pathologe|January 20, 2006
[Hematological side effects of tyrosine kinase inhibition using imatinib]A Schmitt-Graeff, A Hochhaus
Der Internist|February 2, 2013
[Tailored management of chronic myeloid leukemia]A Hochhaus, P La Rosée
Leukemia|April 10, 2014
Nicole Muller-Bérat Killmann 1932-2014 Leukemia pioneerR P Gale, A Hochhaus
Leukemia|January 24, 2015
Therapy of older persons with acute myeloid leukemiaR P Gale, A Hochhaus
Leukemia|September 24, 2010
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaE Jabbour, M Deininger, A Hochhaus
Deutsche Medizinische Wochenschrift (1946)|September 30, 2004
[Therapy of chronic myelogenous leukemia in 2004]A Hochhaus, U Berger, R Hehlmann
Leukemia|April 30, 2005
How long will chronic myeloid leukemia patients treated with imatinib mesylate live?J Hasford, M Pfirrmann, A Hochhaus
Pageof 22

Showing results (11-20 of 216) with videos related to

Sort By:
Pageof 22
Leukemia|June 25, 2004
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceA Hochhaus, P La Rosée
Leukemia|December 10, 2025
Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few moreR P Gale, A Hochhaus
Leukemia|December 13, 2024
Mpox in people with haematological cancersR P Gale, A Hochhaus
Der Pathologe|January 20, 2006
[Hematological side effects of tyrosine kinase inhibition using imatinib]A Schmitt-Graeff, A Hochhaus
Der Internist|February 2, 2013
[Tailored management of chronic myeloid leukemia]A Hochhaus, P La Rosée
Leukemia|April 10, 2014
Nicole Muller-Bérat Killmann 1932-2014 Leukemia pioneerR P Gale, A Hochhaus
Leukemia|January 24, 2015
Therapy of older persons with acute myeloid leukemiaR P Gale, A Hochhaus
Leukemia|September 24, 2010
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaE Jabbour, M Deininger, A Hochhaus
Deutsche Medizinische Wochenschrift (1946)|September 30, 2004
[Therapy of chronic myelogenous leukemia in 2004]A Hochhaus, U Berger, R Hehlmann
Leukemia|April 30, 2005
How long will chronic myeloid leukemia patients treated with imatinib mesylate live?J Hasford, M Pfirrmann, A Hochhaus
Pageof 22